ANG2008 - Preventing nerve cell death

ANG2008 is a fusion of Angiopep-2 and the glial cell-derived neurotrophic factor (GDNF) protein. GDNF is a nerve growth factor, a protein that promotes the survival of many types of neurons, including those responsible for producing dopamine. Unfortunately, GDNF does not cross the blood-brain barrier.

A successful disease modifying therapy would stimulate dopamine production and prevent neuron degeneration, and therefore have the potential to treat not only Parkinson's disease but also amyotrophic lateral sclerosis (ALS), as well as other related neurodegenerative disorders.

Preclinical studies show promise of ANG2008 in treating Parkinson’s disease

In early studies, ANG2008 is reaching its target in the brain and therefore has potential in preventing the destruction of motorneurons that cause the symptoms of Parkinson’s disease.

In vitro studies demonstrate ANG2008 has similar binding to the GDNF receptor, and activates the GFR1α /Ret signaling pathways in neuroblastoma cells. In vivo studies are ongoing in relevant animal models.

Learn more about Angiopeps and the EPiC technology platform. > More